Published in Int J Stroke on April 01, 2010
Is patent foramen ovale a modifiable risk factor for stroke recurrence? Stroke (2010) 1.83
The brain's heart - therapeutic opportunities for patent foramen ovale (PFO) and neurovascular disease. Pharmacol Ther (2013) 1.07
Current proceedings of childhood stroke. Stroke Res Treat (2011) 0.75
Decline in mean platelet volume in patients with patent foramen ovale undergoing percutaneous closure. Cardiovasc J Afr (2014) 0.75
Increased prevalence of potential right-to-left shunting in children with sickle cell anaemia and stroke. Br J Haematol (2016) 0.75
The Role of Patent Foramen Ovale in Cryptogenic Stroke. Noro Psikiyatr Ars (2016) 0.75
Clinical clues to paradoxical embolism. Int J Stroke (2010) 0.75
Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells. J Exp Med (1992) 5.32
Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med (2001) 5.09
Percutaneous closure of patent foramen ovale in patients with paradoxical embolism: long-term risk of recurrent thromboembolic events. Circulation (2000) 3.75
Angiographic follow-up after placement of a self-expanding coronary-artery stent. N Engl J Med (1991) 2.97
Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty. Lancet (1988) 2.90
Is the development of myocardial tolerance to repeated ischemia in humans due to preconditioning or to collateral recruitment? J Am Coll Cardiol (1999) 2.70
Long-term results after fluoroscopy-guided closure of patent foramen ovale for secondary prevention of paradoxical embolism. Heart (2007) 2.40
Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiography. Am J Cardiol (1992) 2.19
Percutaneous closure of patent foramen ovale reduces the frequency of migraine attacks. Neurology (2004) 2.09
Recommendations on stent manufacture, implantation and utilization. Study Group of the Working Group on Coronary Circulation. Eur Heart J (1997) 2.05
Promotion of collateral growth by granulocyte-macrophage colony-stimulating factor in patients with coronary artery disease: a randomized, double-blind, placebo-controlled study. Circulation (2001) 2.02
Treatment of renovascular hypertension with percutaneous transluminal dilatation of a renal-artery stenosis. Lancet (1978) 2.00
Restenosis after successful coronary angioplasty in patients with single-vessel disease. Circulation (1986) 1.99
Surgical management of complications after transcatheter closure of an atrial septal defect or patent foramen ovale. J Thorac Cardiovasc Surg (2000) 1.94
Clinical and radiological predictors of recanalisation and outcome of 40 patients with acute basilar artery occlusion treated with intra-arterial thrombolysis. J Neurol Neurosurg Psychiatry (2004) 1.90
Patent foramen ovale and neurosurgery in sitting position: a systematic review. Br J Anaesth (2009) 1.82
Coronary collateral quantitation in patients with coronary artery disease using intravascular flow velocity or pressure measurements. J Am Coll Cardiol (1998) 1.70
HDF2, the second subunit of the Ku homologue from Saccharomyces cerevisiae. J Biol Chem (1996) 1.68
A randomized evaluation of early revascularization to treat shock complicating acute myocardial infarction. The (Swiss) Multicenter Trial of Angioplasty for Shock-(S)MASH. Eur Heart J (1999) 1.66
Physiologically assessed coronary collateral flow and intracoronary growth factor concentrations in patients with 1- to 3-vessel coronary artery disease. Circulation (1999) 1.66
Comparison of intra-arterial thrombolysis with conventional treatment in patients with acute central retinal artery occlusion. J Neurol Neurosurg Psychiatry (2005) 1.63
Outcome of patients with cryptogenic stroke and patent foramen ovale. J Neurol Neurosurg Psychiatry (2002) 1.63
Plaque sealing by coronary angioplasty. Cathet Cardiovasc Diagn (1995) 1.62
Stroke events, and case fatalities in Switzerland based on hospital statistics and cause of death statistics. Swiss Med Wkly (2009) 1.62
Efficacy of drug eluting stents in patients with and without diabetes mellitus: indirect comparison of controlled trials. Heart (2005) 1.61
Stenting of superior vena cava and inferior vena cava for symptomatic narrowing after repeated atrial surgery for D-transposition of the great vessels. Br Heart J (1991) 1.59
A prospective randomized trial comparing stenting to internal mammary artery grafting for proximal, isolated de novo left anterior coronary artery stenosis: the SIMA trial. Stenting vs Internal Mammary Artery. Mayo Clin Proc (2000) 1.58
Interleukin 1-alpha and tumor necrosis factor-alpha induce oxygen radical production in mesangial cells. Kidney Int (1990) 1.57
Clinical and angiographic outcome of patients with mild coronary lesions treated with balloon angioplasty or coronary stenting. Implications for mechanical plaque sealing. Eur Heart J (2003) 1.55
Total occlusion trial with angioplasty by using laser guidewire. The TOTAL trial. Eur Heart J (2000) 1.54
Quantitatively assessed coronary collateral circulation and restenosis following percutaneous revascularization. Eur Heart J (2000) 1.49
Aortic dissection as complication of percutaneous transluminal coronary angioplasty. Cathet Cardiovasc Diagn (1992) 1.48
Indications for intracoronary stent placement: the european view. Working Group on Coronary Circulation of the European Society of Cardiology. Eur Heart J (1999) 1.46
Frequency distribution of collateral flow and factors influencing collateral channel development. Functional collateral channel measurement in 450 patients with coronary artery disease. J Am Coll Cardiol (2001) 1.46
Impossibility to cross a stenotic mitral valve with the Inoue balloon: success with a modified technique. Indian Heart J (1994) 1.44
Interventional cardiology in Europe 1994. Working Group Coronary Circulation of the European Society of Cardiology. Eur Heart J (1998) 1.44
Tetrahydrobiopterin improves endothelial function in patients with coronary artery disease. J Cardiovasc Pharmacol (2000) 1.43
Acute occlusion after percutaneous transluminal coronary angioplasty--a new approach. Circulation (1983) 1.40
Left main coronary angioplasty in a 10-year-old boy with homozygous familial hypercholesterolemia. Cathet Cardiovasc Diagn (1993) 1.40
Coronary interventions in Europe 1992. The Working Group on Coronary Circulation of the European Society of Cardiology. Eur Heart J (1995) 1.39
[Cardiac interventions in Switzerland 1992. PTCA and Fibrinolysis Work Group of the Swiss Cardiology Association]. Schweiz Med Wochenschr (1994) 1.39
[Treatment of fallopian tube pregnancies with prostaglandins]. Geburtshilfe Frauenheilkd (1991) 1.38
Prolonged heparin after uncomplicated coronary interventions: a prospective, randomized trial. Am Heart J (1998) 1.38
[Coronary angioplasty without surgical standby: a prospective study]. G Ital Cardiol (1992) 1.37
Interventional cardiology in Europe 1995. Working Group Coronary Circulation of the European Society of Cardiology. Eur Heart J (1999) 1.36
Ultrasound-guided compression repair for treatment of femoral artery pseudoaneurysm: acute and follow-up results. Cathet Cardiovasc Diagn (1996) 1.27
Triple and quadruple spontaneous cervical artery dissection: presenting characteristics and long-term outcome. J Neurol Neurosurg Psychiatry (2008) 1.26
Mechanism of ischemic infarct in spontaneous carotid dissection. Stroke (2004) 1.25
Balloon angioplasty for acute myocardial infarction. Was it buried alive? Circulation (1990) 1.24
Prevalence and size of directly detected patent foramen ovale in migraine with aura. Neurology (2005) 1.24
Molecular cloning and partial nucleotide sequence of human papillomavirus type 1a DNA. Virology (1982) 1.22
Induction of oxidative stress by okadaic acid is required for activation of transcription factor NF-kappa B. J Biol Chem (1995) 1.21
Should coronary arteries with less than 60% diameter stenosis be treated by angioplasty? Circulation (1983) 1.21
Nature of T-cell macrophage interaction in helper-cell induction in vitro. II. Two stages of T-helper-cell differentiation analyzed in irradiation and allophenic chimeras. J Exp Med (1979) 1.20
Intra-arterial thrombolysis in 24 consecutive patients with internal carotid artery T occlusions. J Neurol Neurosurg Psychiatry (2003) 1.17
Vascular risk factors and morphometric data in cervical artery dissection: a case-control study. J Neurol Neurosurg Psychiatry (2009) 1.16
Synthesis of either Fe- or Mn-superoxide dismutase with an apparently identical protein moiety by an anaerobic bacterium dependent on the metal supplied. J Biol Chem (1982) 1.16
Percutaneous transluminal coronary angioplasty for chronic total coronary arterial occlusion. Am J Cardiol (1987) 1.15
Improvement of left ventricular contraction and relaxation synchronism after recanalization of chronic total coronary occlusion by angioplasty. J Am Coll Cardiol (1987) 1.14
Risk of side branch occlusion during coronary angioplasty. Am J Cardiol (1984) 1.13
Single-dose ciprofloxacin at 100 versus 250 mg for treatment of uncomplicated urinary tract infections in women. Antimicrob Agents Chemother (1987) 1.11
Sleep need in adolescents: a longitudinal approach. Sleep (1988) 1.11
Kissing balloon coronary angioplasty. Am J Cardiol (1984) 1.10
Nature of T cell-macrophage interaction in helper cell induction in vitro. I. Evidence for genetic restriction of T cell-macrophage interactions prior to T cell priming. Eur J Immunol (1978) 1.10
Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes. Horm Metab Res (2005) 1.08
Long-term results of successful and failed angioplasty for chronic total coronary arterial occlusion. Am J Cardiol (1990) 1.07
Foreseeing complications of coronary angioplasty--predicting the unpredictable. Eur Heart J (1999) 1.07
The balance between gluco- and mineralo-corticoid action critically determines inflammatory adipocyte responses. J Endocrinol (2009) 1.07
Is genetically related macrophage factor (GRF) a soluble immune response (Ir) gene product? J Immunol (1979) 1.06
Repeat coronary angioplasty. J Am Coll Cardiol (1984) 1.06
Coronary dissection and total coronary occlusion associated with percutaneous transluminal coronary angioplasty: significance of initial angiographic morphology of coronary stenoses. Circulation (1986) 1.06
Coronary pacing during percutaneous transluminal coronary angioplasty. Circulation (1985) 1.06
Effect of nifedipine on recurrent stenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol (1986) 1.04
Novel management strategy for patients with suspected pulmonary embolism. Eur Heart J (2003) 1.04
Simultaneous intracoronary velocity- and pressure-derived assessment of adenosine-induced collateral hemodynamics in patients with one- to two-vessel coronary artery disease. J Am Coll Cardiol (1999) 1.04
Therapeutic strategy with total coronary artery occlusions. Am J Cardiol (1997) 1.03
Symptomatic intracranial haemorrhage after intra-arterial thrombolysis in acute ischaemic stroke: assessment of 294 patients treated with urokinase. J Neurol Neurosurg Psychiatry (2007) 1.03
Recanalisation of middle cerebral artery occlusion after intra-arterial thrombolysis: different recanalisation grading systems and clinical functional outcome. J Neurol Neurosurg Psychiatry (2005) 1.02
Acute complications of elective coronary angioplasty: a review of 500 consecutive procedures. Br Heart J (1988) 1.02
Age-dependent differences in demographics, risk factors, co-morbidity, etiology, management, and clinical outcome of acute ischemic stroke. J Neurol (2008) 1.00
The European registry of cardiac catheter interventions 1996. Eur Heart J (2001) 1.00
Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease. Circulation (1998) 0.99
Diffusion-weighted MRI in acute spinal cord ischaemia. Neuroradiology (2003) 0.99
Direct intracoronary evidence of collateral steal in humans. Circulation (1997) 0.98
Percutaneous transluminal angioplasty of right and left internal mammary artery grafts. Chest (1986) 0.97
Evolution of percutaneous transluminal coronary angioplasty in Europe from 1992-1996. Eur Heart J (2001) 0.96
Percutaneous closure of patent foramen ovale: impact of device design on safety and efficacy. Heart (2004) 0.94
Transluminal coronary angioplasty--state of the art 1984. Acta Med Scand Suppl (1985) 0.93
Coronary wedge pressure in relation to spontaneously visible and recruitable collaterals. Circulation (1987) 0.93
Relative risk analysis of angiographic predictors of restenosis within the coronary Wallstent. Circulation (1991) 0.93
Prognosis after percutaneous closure of patent foramen ovale for paradoxical embolism. Neurology (2001) 0.92
Use of coronary angioplasty, bypass surgery, and conservative therapy for treatment of coronary artery disease over the past decade. Eur Heart J (1998) 0.92
Results of transvenous occlusion of secundum atrial septal defects with the fourth generation buttoned device: comparison with first, second and third generation devices. International Buttoned Device Trial Group. J Am Coll Cardiol (2000) 0.92
Induction or elimination of tumor-specific immunity against a chemically-induced rat tumor using auto-anti-idiotypic immunity. Int J Cancer (1982) 0.91
Quantitative angiographic follow-up of the coronary Wallstent in native vessels and bypass grafts (European experience--March 1986 to March 1990). Am J Cardiol (1992) 0.91
Benign coronary perforation during percutaneous transluminal coronary angioplasty. Br Heart J (1985) 0.91